In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines

Jean‐Louis Merlin(Centre National de la Recherche Scientifique), Nicolas Bachmann(Délégation Centre-Est)

Annals of Oncology

November 1, 2002

10.1093/annonc/mdf263

Cited by 82

Related Papers

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

|PubMed|1998|114

Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results.

|PubMed|1995|21